retain: risk-enabled therapy after neoadjuvant chemo for mibc
Published 1 year ago • 98 plays • Length 11:44Download video MP4
Download video MP3
Similar videos
-
5:13
risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some mibc
-
0:15
next-generation immunotherapy for #nmibc #bladdercancer #cancerresearch #cancer #news
-
4:08
hcrn gu 16-257: neoadjuvant therapy for patients with mibc
-
5:49
dr. roger li on the growing role of neoadjuvant immunotherapy in mibc
-
0:27
cretostimogene plus pembrolizumab for bcg-unresponsive nmibc with cis #bladdercancer #cancer #news
-
4:24
retain bladder: a risk-adapted approach to muscle invasive bladder cancer
-
11:12
dr. raj satkunasivam on mibc neoadjuvant approaches for local, distant control
-
16:42
neoadjuvant therapy for mibc in the genomic era
-
20:29
neoadjuvant and adjuvant chemotherapy in bladder cancer
-
2:20
neoadjuvant therapy for patients with upper tract urothelial carcinoma
-
8:02
dr. roger li on the event-free survival benefit of neoadjuvant immunotherapy in mibc
-
10:15
neoadjuvant, adjuvant therapy in upper, lower tract urothelial disease with drs. grivas, wallis
-
1:35
what is neoadjuvant therapy?
-
2:23
envision: ugn-102 and chemoablation for low-grade, intermediate-risk nmibc
-
2:25
reducing risk in residual breast cancer
-
6:43
systemic treatment for recurrent rcc
-
17:42
what do we do after complete response to neoadjuvant therapy?
-
1:29:54
examining the state of the science on new therapies in bladder cancer
-
3:55
dr. raj satkunasivam on neoadjuvant sasanlimab and sbrt for cisplatin-ineligible mibc